3 Relatively Safe Stocks to Buy Right Now

Group 1: Abbott Laboratories - Abbott Laboratories is considered a safe investment within the healthcare sector due to its diverse operations and strong dividend history [2][4] - The company offers an above-average dividend yield of 1.9%, with 53 consecutive years of dividend increases, indicating reliable income potential [3][5] - In the last year, Abbott generated $19 billion from medical devices,$9 billion from diagnostics, $8 billion from nutritional sales, and$5 billion from established pharmaceuticals, resulting in an overall growth rate of just under 5% [4][5] Group 2: AbbVie - AbbVie has effectively navigated the challenges of losing patent protection for its top-selling drug, Humira, which accounted for 65% of its revenue by 2017 [6][7] - The company has introduced successor products, Skyrizi and Rinvoq, projected to generate combined sales of $24 billion in 2023 and over$31 billion by 2027 [8] - AbbVie is recognized as a Dividend King with 53 consecutive years of dividend increases and offers a forward dividend yield of 3.25% [9] Group 3: Johnson & Johnson - Johnson & Johnson maintains a AAA credit rating, reflecting the strength of its balance sheet despite ongoing lawsuits related to talc-based products [11] - The company reported a 4.3% year-over-year increase in revenue to $88.8 billion and an 11.3$5.79 in 2024 [12] - Johnson & Johnson's recent cancer drug, Carvykti, saw sales grow by 92.7% year over year to $963 million, contributing to its strong growth outlook [13][14]